Tau PET阳性预测阿尔茨海默病驱动的临床相关认知下降并与共病病例对比:ADNI研究中的概念验证
研究基于ADNI数据集396名基线有Aβ和tau PET且随访≥2年的认知正常或受损个体,评估tau PET识别Aβ(+)者前瞻性病情进展的准确性。基线tau PET摄取可区分Aβ(+)快速下降者与Aβ(-)及Aβ(+)慢速下降者,并线性关联Aβ(+)者年认知下降率。孤立Aβ(+)者的认知下降可能与多病共存背景下的AD谱系变化(即混合性AD)相关。
要点
- 基线tau PET摄取在Aβ(+)快速下降者中高于Aβ(-)快速/慢速下降者及Aβ(+)慢速下降者,与基线认知状态无关。
- 基线tau PET摄取识别MCI Aβ(+)转化者和Aβ(+)快速下降者的曲线下面积分别为0.85和0.87(复合颞叶感兴趣区)。
- 快速下降者中最常见生物标志物谱为Aβ(+)T(+)(49%)和Aβ(+)T(-)(27%)。
核心结论
- 研究提示高tau PET摄取与Aβ病理及加速认知下降相耦合。
- 在孤立Aβ(+)病例中,认知下降可能与多病共存背景下AD谱系内的变化相关,即混合性AD。
研究设计与样本
- 从阿尔茨海默病神经影像学倡议(ADNI)数据集中选取396名基线有Aβ和tau PET且随访≥2年的认知正常或受损个体。
- 参与者基于临床转化(即诊断改变)或认知衰退(快速下降者 vs. 慢速下降者,使用个体年认知下降率的数据驱动聚类)进行二分组。
主要发现
- 基线tau PET摄取在Aβ(+)快速下降者中高于Aβ(-)快速/慢速下降者及Aβ(+)慢速下降者,与基线认知状态无关。
- 基线tau PET摄取识别MCI Aβ(+)转化者的曲线下面积为0.85,识别Aβ(+)快速下降者的曲线下面积为0.87(复合颞叶感兴趣区)。
- 基线tau PET摄取与Aβ(+)个体年认知下降率线性相关。
- T(+)个体在很大程度上是Aβ(+)者及聚类为快速下降者亚组的一部分。
- 快速下降者(n=70)中最常见生物标志物谱为Aβ(+)T(+)(n=34,49%)和Aβ(+)T(-)(n=19,27%)。
关键数值与推荐
- 基线Aβ负荷在Aβ(+)T(+)快速下降者中(M=83.03±31.42CL)高于Aβ(+)T(-)快速下降者(M=63.67±26.75CL),p值=0.038。
- 抑郁诊断在Aβ(+)T(-)快速下降者中较Aβ(+)T(+)快速下降者更普遍(47% vs. 15%,p值=0.021)。
- FDG PET低代谢模式不提示AD在Aβ(+)T(-)快速下降者中较Aβ(+)T(+)快速下降者更普遍(86% vs. 50%,p值=0.039)。
- 基线tau PET摄取识别MCI Aβ(+)转化者的曲线下面积为0.85,识别Aβ(+)快速下降者的曲线下面积为0.87(复合颞叶感兴趣区)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
β-amyloid (Aβ) pathology is not always coupled with Alzheimer's disease (AD) relevant cognitive decline. We assessed the accuracy of tau PET to identify Aβ(+) individuals who show prospective disease progression. 396 cognitively unimpaired and impaired individuals with baseline Aβ and tau PET and a follow-up of ≥ 2 years were selected from the Alzheimer's Disease Neuroimaging Initiative dataset. The participants were dichotomously grouped based on either clinical conversion (i.e., change of diagnosis) or cognitive deterioration (fast (FDs) vs. slow decliners (SDs)) using data-driven clustering of the individual annual rates of cognitive decline. To assess cognitive decline in individuals with isolated Aβ(+) or absence of both Aβ and tau (T) pathologies, we investigated the prevalence of non-AD comorbidities and FDG PET hypometabolism patterns suggestive of AD. Baseline tau PET uptake was higher in Aβ(+)FDs than in Aβ(-)FD/SDs and Aβ(+)SDs, independently of baseline cognitive status. Baseline tau PET uptake identified MCI Aβ(+) Converters and Aβ(+)FDs with an area under the curve of 0.85 and 0.87 (composite temporal region of interest) respectively, and was linearly related to the annual rate of cognitive decline in Aβ(+) individuals. The T(+) individuals constituted largely a subgroup of those being Aβ(+) and those clustered as FDs. The most common biomarker profiles in FDs (n = 70) were Aβ(+)T(+) (n = 34, 49%) and Aβ(+)T(-) (n = 19, 27%). Baseline Aβ load was higher in Aβ(+)T(+)FDs (M = 83.03 ± 31.42CL) than in Aβ(+)T(-)FDs (M = 63.67 ± 26.75CL) (p-value = 0.038). Depression diagnosis was more prevalent in Aβ(+)T(-)FDs compared to Aβ(+)T(+)FDs (47% vs. 15%, p-value = 0.021), as were FDG PET hypometabolism pattern not suggestive of AD (86% vs. 50%, p-value = 0.039). Our findings suggest that high tau PET uptake is coupled with both Aβ pathology and accelerated cognitive decline. In cases of isolated Aβ(+), cognitive decline may be associated with changes within the AD spectrum in a multi-morbidity context, i.e., mixed AD.
引用
- Ioannou K, Bucci M, Tzortzakakis A, et al. Tau PET positivity predicts clinically relevant cognitive decline driven by Alzheimer's disease compared to comorbid cases; proof of concept in the ADNI study. Mol Psychiatry. 2024. PMID: 39179903. doi:10.1038/s41380-024-02672-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。